Fritextsökning
Artiklar per år
Innehållstyper
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs are high, and demand is weak”, says the division manager at Rise to Life Science Sweden.
-
Novo Nordisk establishes new factory in Denmark
Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in connection with losing his company, Tataa Biocenter.
-
Norwegian cancer research companies merge
The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.
-
Lilly recruits top Swedish researcher in Alzheimer´s
One of Sweden's leading Alzheimer's researchers, Oskar Hansson, has been recruited by pharma giant Eli Lilly and will be moving to the USA.
-
600 million SEK for life science - "Should not be the country of moderation"
Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessible to more people. “Our overall ambition is to reduce costs a hundredfold”, says professor Johan Rockberg at KTH Royal Institute of Technology in Stockholm.
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
Novo Nordisk to invest billions in new quality control lab
Novo Nordisk has announced plans to invest 2.9 billion Danish kroner in order to establish a new quality control laboratory in Hillerød in northern Zealand, Denmark.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks approved treatment alternatives. "We can't do that on our own – our entire R&D activities are about working together with others," says the company's CEO Jens Lindberg.
-
Orbán's extended arm becomes health commissioner in the EU
Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hungarian prime minister Viktor Orbán, is seen as a controversial figure due to his opposition to abortion and for calling EU members ”idiots.”
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming in the market", says Daniel Lucas, Managing Director Nordic Countries at the American pharmaceutical giant Eli Lilly.
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
New large lab building in Lund inaugurated – here are the companies moving in
Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employment and Integration Mats Persson (L) and construction contractor Mats Paulsson.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the decision to create a joint profile for the two cities is strongly supported. He mentions that around 50 stakeholders were asked last winter if they were in favour of a joint cluster and that “the answer was a resounding yes”.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the billion-selling GLP1 analogues. ‘‘Basically, I expect all the beneficial effects that they have, but not the same side effect profile,’’ company founder Dorte X Gram said in an interview with Life Science Sweden.
-
Stockholm and Uppsala jointly form a life science cluster
Stockholm and Uppsala are strengthening cooperation in medical research and biotech.
-
Leo Pharma to cut 200 jobs and reorganize
Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.
-
GSK pays 2.2 billion dollars to settle Zantac lawsuits
British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against the company in the U.S. that alleged its discontinued drug Zantac caused cancer.
-
AstraZeneca to use American AI platform for cancer trials
In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.
BREAKING